Edwards Lifesciences, a provider of science of heart valves and hemodynamic monitoring, agreed to acquire Innovalve, a medical device company developing catheter-delivered heart valve therapies. Financial terms were not disclosed. “Building on our learnings of the complexity of mitral disease, we know there is a need for a differentiated range of therapies for these patients. Edwards’ SAPIEN M3 remains on track to become the first approved transfemoral TMVR system in Europe by the end of 2025. We believe the Innovalve technologies, paired with Edwards’ deep mitral expertise, will enable a TMVR platform that will expand the treatable population,” Daveen Chopra, Innovalve Vice President.